The FDA has accepted Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the primary and solely subcutaneous, chemo-free therapy for sufferers with EGFR-mutated non-small cell lung most...
Lively Biotech has obtained optimistic suggestions from regulators on a protocol modification to its ongoing proof-of-concept scientific trial evaluating tasquinimod in sufferers with myelofibrosis, a...
As survival charges enhance, extra persons are residing longer with kidney most cancers. Together with longer survival, nonetheless, comes a rising consciousness...
For sufferers identified with superior hormone receptor (HR)–optimistic breast most cancers, rising therapies and tailor-made remedy methods are shifting the panorama in...
Metastatic breast most cancers therapy with the mixture of PCS6422 and capecitabine (NGC-Cap) might improve the cancer-killing energy of therapy with out...
